HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Repurposing the antioxidant and anti-inflammatory agent N-acetyl cysteine for treating COVID-19.

Abstract
Although several considerations have been raised suggesting a beneficial effect of N-acetyl cysteine (NAC) for the treatment of severe acute respiratory syndrome coronavirus 2 infection, there is currently no clinical evidence that NAC truly prevents coronavirus disease 2019 (COVID-19), reduces the severity of the disease, or improves the outcome. Appropriately designed clinical trials are warranted to prove or disprove a therapeutic effect of NAC for COVID-19 patients.
AuthorsJosef Finsterer, Fulvio A Scorza, Carla A Scorza, Ana C Fiorini
JournalWorld journal of virology (World J Virol) Vol. 11 Issue 1 Pg. 82-84 (Jan 25 2022) ISSN: 2220-3249 [Print] United States
PMID35117973 (Publication Type: Journal Article)
Copyright©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: